ALDH1A1 (RALDH1)

Aldehyde dehydrogenase 1A1 (ALDH1A1) is the rate-limiting enzyme for retinoic acid synthesis in adult liver, hematopoietic stem cells (HSCs), and dopaminergic neurons of the substantia nigra. It catalyzes the NAD⁺-dependent irreversible oxidation of retinaldehyde to all-trans retinoic acid (atRA), and also detoxifies reactive lipid aldehydes — particularly 4-hydroxynonenal (4-HNE) — generated during oxidative stress. ALDH1A1 is one of three RALDH paralogs (RALDH1/2/3 encoded by ALDH1A1/1A2/1A3); the paralogs share the same catalytic reaction but differ sharply in tissue distribution and developmental expression timing.

Identity

Property	Value
UniProt	P00352 (ALDH1A1_HUMAN)
NCBI Gene	216
HGNC symbol	ALDH1A1 (HGNC:402)
Ensembl	ENSG00000165092
Mouse ortholog	Aldh1a1 (one-to-one; high conservation)
Sequence length	501 amino acids (~55 kDa)
Subcellular location	Cytoplasm / cytosol; also detected in axonal projections
GenAge entry	not listed — not a canonical pro-longevity or lifespan gene in HAGR as of 2026-05-19 needs-canonical-id

Key functional domains and PTMs

ALDH1A1 belongs to the aldehyde dehydrogenase superfamily and adopts a homotetrameric structure. The active site catalytic Cys residue (Cys303 in human) attacks the aldehyde carbonyl of the substrate (retinaldehyde, 4-HNE, or other aliphatic aldehydes). Post-translational modifications identified in UniProt include:

N-terminal acetylation at Ser-2 (co-translational)
Lysine acetylation at multiple sites (K91, K128, K252, K353, K367, K410, K419, K435, K495) — putative regulatory sites; biological significance largely unexplored
Phosphorylation at Thr-337 and Ser-413

Structural differences among ALDH1A subfamily members (ALDH1A1, 1A2, 1A3) are subtle at the active-site cleft but create distinct substrate selectivity and inhibitor-binding profiles — a basis for isoform-selective chemical probe design ¹. The substrate-binding pocket volumes differ: 534 / 387 / 387 Å³ for ALDH1A1 / ALDH1A2 / ALDH1A3 respectively, with ALDH1A1 having the largest pocket ¹.

Catalytic function: retinaldehyde → retinoic acid

ALDH1A1 is one of three mammalian RALDH enzymes that collectively mediate the irreversible bottleneck step in the vitamin A → retinoic acid pathway:

Dietary retinyl esters → retinol
        ↓  ADH/RDH (reversible; alcohol dehydrogenases)
  All-trans retinaldehyde
        ↓  ALDH1A1 / ALDH1A2 / ALDH1A3  ← [this enzyme; rate-limiting; essentially irreversible]
  All-trans retinoic acid (atRA / tretinoin)
        ↓  RARα/β/γ : RXR heterodimers → RARE-driven transcription
  Target genes: CYP26A1, HOXA1, CRABP2, RAR-β, p21,...

The irreversibility of RALDH-catalyzed oxidation means ALDH1A1 activity sets the ceiling on local atRA concentration in tissues that lack direct access to systemic retinol. This is pharmacologically relevant for topically applied retinaldehyde: conversion efficiency depends on ALDH1A expression in keratinocytes and dermal fibroblasts, which varies with age and UV exposure history — see retinaldehyde for the skin-context discussion.

Tissue expression and paralog distribution

The three RALDH paralogs occupy non-overlapping tissue niches in adult physiology ²:

Isoform	Gene	Primary adult expression	Key developmental role
RALDH1 (this page)	ALDH1A1	Liver (dominant), HSCs, substantia nigra dopaminergic neurons, retinal pigment epithelium	Postnatal and regenerative atRA synthesis
RALDH2	ALDH1A2	Embryonic mesoderm, heart, lung, gonad, gut	Major embryonic atRA source; Aldh1a2-null mice die in utero
RALDH3	ALDH1A3	Nasal epithelium, olfactory mucosa, ventral retina, anterior pituitary	Head/face morphogenesis; olfactory development

Key distinction: RALDH1 is the dominant postnatal RALDH for systemic retinoic acid homeostasis. RALDH2 is the dominant embryonic source; pituitary RALDH is RALDH2/3, not RALDH1 ³.

needs-human-replication — Tissue-distribution data in the table is derived primarily from rodent studies; quantitative human tissue data for RALDH1 vs RALDH2/3 comparison is sparse in GTEx. gtex-aging-correlation: field is null pending sops/finding-tissue-expression.md lookup.

Aging-relevant biology

1. HSC self-renewal and stem-cell fate

ALDH activity (assessed via the ALDEFLUOR assay, which detects ALDH1A1 in HSCs) is a widely used marker of the most primitive HSC fraction. Inhibition of ALDH with DEAB (N,N-diethylaminobenzaldehyde — a broad ALDH inhibitor, not selective for ALDH1A1) produced a 3.4-fold expansion of SCID-repopulating cells (SRCs) from human cord blood CD34+CD38− cells in ex vivo culture, with retained multilineage engraftment in NOD/SCID mice; this phenotype was reversed by exogenous ATRA (1 µM) and by the RAR-specific agonist TTNPB, establishing that ALDH1A1-driven retinoic acid synthesis (confirmed by DEAB-induced reduction in cEBPε expression, an RAR target) restrains HSC self-renewal ⁴.

This establishes a dual-edged role in aging: ALDH1A1 activity is required for HSC survival and maintenance, but excessive retinoic acid signaling from ALDH1A1 may drive HSC commitment/differentiation at the expense of the quiescent self-renewing pool. Aged bone marrow shows alterations in the ALDEFLUOR-high fraction — whether this reflects primary ALDH1A1 decline or is secondary to niche remodeling is unresolved. contradictory-evidence

Dimension	Status	Notes
Pathway conserved in humans?	yes	ALDEFLUOR-high fraction identifies primitive HSCs in both mouse and human bone marrow
Phenotype (HSC exhaustion with aging)?	yes	Stem cell exhaustion is a canonical hallmark; RALDH1 contribution specifically is unresolved
Replicated in humans?	partial	ALDEFLUOR used clinically for HSC isolation; DEAB mechanistic studies are human ex-vivo

2. Lipid-aldehyde detoxification (4-HNE and oxidative damage)

4-Hydroxynonenal (4-HNE) is the major lipid-peroxidation aldehyde generated during mitochondrial ROS overproduction — a central feature of aging. ALDH1A1 is a principal cytosolic enzyme for 4-HNE detoxification ⁵. In neuroblastoma cells, ALDH1A1 overexpression reduced protein-HNE adduct formation and caspase-3 activation under oxidative challenge ⁶.

This positions ALDH1A1 as a first-line oxidative-stress buffer: its loss or enzymatic inhibition accelerates lipid-adduct accumulation in lens, brain, and liver. Age-associated decline in ALDH activity has been documented in several tissues, though whether ALDH1A1 specifically is the rate-limiting isoform for 4-HNE clearance in aging contexts is not well resolved. no-mechanism

3. Dopaminergic neuron identity and Parkinson’s disease vulnerability

ALDH1A1 is a molecular marker for a specific subpopulation of substantia nigra dopaminergic (SN-DA) neurons — the ALDH1A1+ (DA1A) subset — identified by single-cell qPCR profiling of 159 mouse midbrain DA neurons ⁷. This subset shows preferential vulnerability in MPTP-induced parkinsonism in mice: ALDH1A1+ (DA1A) neurons showed a 66.2% diminution after MPTP vs saline (p=0.001), compared to only 39.1% loss in the remaining (DA1B) DA neurons (p=0.001). In human Parkinson’s disease (PD); snRNA-seq of ~84,000 nuclei from the SN in PD cases vs controls (15 PD / 14 controls) identified ALDH1A1 among 28 cell markers shared across multiple TH-enriched depleted cell types — dopaminergic Neurons0, Astrocytes2, Microglia1, and Oligos2 — confirming ALDH1A1 as a pan-TH-enriched population marker depleted in PD across both neuronal and glial subpopulations ⁸.

ALDH1A1 is proposed to serve a dual protective function in these neurons: (1) synthesizing atRA to support dopamine neuron survival signaling, and (2) detoxifying DOPAL (3,4-dihydroxyphenylacetaldehyde), the toxic aldehyde intermediate produced when monoamine oxidase (MAO) degrades dopamine. Loss of ALDH1A1 activity in aged SN neurons may therefore combine impaired neuroprotective retinoic acid signaling with DOPAL accumulation — a “double-hit” mechanism. no-mechanism — the relative contributions of the retinoid vs DOPAL-detox functions in PD are debated.

Dimension	Status	Notes
Pathway conserved in humans?	yes	ALDH1A1+ SN-DA subset is present in human brain
Phenotype (DA neuron loss) in humans?	yes	Core PD pathology
ALDH1A1 causal vs marker?	contested	contradictory-evidence

4. Adipose tissue and metabolic regulation

In adipose tissue, ALDH1A1 synthesizes atRA from locally stored retinaldehyde, which in turn activates RAR-dependent suppression of PPARγ — the master adipogenic transcription factor. Adipose-specific atRA signaling via RALDH1 thus opposes adipogenesis and modulates visceral fat expansion ⁹. Paradoxically, Raldh1 knockout mice show enhanced adiposity during adolescence via a retinal-independent, cell-autonomous mechanism in preadipocytes ¹⁰, suggesting the enzyme’s adipose functions extend beyond simple atRA production.

ALDH1A1 expression is sex-specific in fat depots — higher in females — which may contribute to sex differences in obesity susceptibility and metabolic aging trajectories ².

5. Retinoid-axis decline in aged skin

As discussed in retinaldehyde, RALDH-mediated conversion is the rate-limiting step controlling local atRA levels in skin. If ALDH1A1 expression or activity declines in aged keratinocytes and dermal fibroblasts — a plausible outcome given the general age-associated decline in ALDH activity — the effective potency of topically applied retinaldehyde would narrow relative to younger skin. This has not been quantitatively characterized in human skin biopsies stratified by age. needs-human-replication

The Falckenhayn 2024 epigenetic context referenced in the seeding brief is noted here; DNA methylation changes at the ALDH1A1 locus with age may reduce transcription in some tissues — however, the specific Falckenhayn data were not retrieved and this connection should not be treated as verified. unsourced

Paralog comparison and isoform selectivity

Feature	ALDH1A1 (RALDH1)	ALDH1A2 (RALDH2)	ALDH1A3 (RALDH3)
Adult dominant tissue	Liver, HSCs, SN neurons	Lung, heart, kidney	Nasal epithelium, olfactory
Embryonic lethality of KO	No (Aldh1a1-KO viable)	Yes	No (but craniofacial defects)
4-HNE detox activity	Yes (major)	Limited data	Limited data
DOPAL detox (dopamine catabolism)	Yes	No (not expressed in SN)	No
Cancer stem-cell marker use	ALDEFLUOR assay primary target	Secondary contributor	Secondary contributor
Selective inhibitor	DEAB (broad ALDH inhibitor), NCT-501 (ALDH1A1-selective, reported in other literature) unsourced	—	—

The availability of ALDH1A1-selective inhibitors (NCT-501 and related compounds) creates pharmacological leverage for HSC expansion protocols and potential cancer-stem-cell targeting; no aging indication is currently in clinical development. needs-human-replication unsourced — NCT-501 selectivity claim requires a separate citation; the Pequerul 2020 structural paper does not characterize NCT-501.

Druggability

Open Targets platform query for ENSG00000165092 was unavailable via REST at time of seeding; tier-2 assignment reflects: (1) DEAB is a broad ALDH inhibitor in wide research use; the Pequerul 2020 structural paper ¹ provides detailed kinetic characterization of ALDH1A subfamily but does not characterize ALDH1A1-selective probes such as NCT-501 — NCT-501 selectivity requires a separate citation; (2) no FDA-approved drug targets ALDH1A1 specifically for any indication; (3) no clinical trials active for ALDH1A1-targeted aging intervention (ClinicalTrials.gov query, 2026-05-19). Aging-context druggability is therefore tier 2 pending confirmation. no-opentargets-entry — confirm via Open Targets on verification pass.

Pathway membership

retinoid-signaling — primary pathway; RALDH1 is the rate-limiting enzymatic node for atRA synthesis in postnatal tissues stub
insulin-igf1 — atRA-driven RAR activation intersects the insulin/IGF-1 axis at the level of FOXO transcription factor regulation (contested; indirect)

Known interactors

rar-alpha, rar-gamma — nuclear receptors downstream of atRA product
CRALBP (cellular retinaldehyde-binding protein) — substrate channeling in retinal pigment epithelium
NADP⁺/NAD⁺ — cofactor; NAD⁺ is the electron acceptor; relevant to NAD⁺ decline in aging

Cross-references

retinaldehyde — substrate; see rate-limiting conversion discussion
retinol — upstream precursor (two enzymatic steps above atRA)
tretinoin — product (atRA); direct RAR ligand
stem-cell-exhaustion — hallmark linked via HSC self-renewal role
loss-of-proteostasis — hallmark linked via 4-HNE detoxification and proteotoxic-stress buffering
mitochondrial-dysfunction — hallmark linked via ROS → 4-HNE → ALDH1A1 substrate load
sasp — DOPAL/aldehyde accumulation downstream of ALDH1A1 loss may potentiate inflammatory signaling in aging neurons
nad-precursors — NAD⁺ availability influences ALDH1A1 enzymatic capacity; age-related NAD⁺ decline (#gap/no-mechanism for this specific link)

Limitations and gaps

No aging-specific human genetic study. No GWAS or Mendelian randomization study has tested ALDH1A1 as a causal driver of any aging phenotype. mr-causal-evidence: not-tested. needs-human-replication
ALDH1A1 expression in aged human tissues is poorly characterized. The assertion that RALDH activity declines with age rests mainly on indirect or rodent data. Human biopsy data stratified by age for liver, skin, and bone marrow are lacking. unsourced
Falckenhayn 2024 epigenetic context was not retrieved. The seeding brief cited epigenetic context from Falckenhayn 2024; this could not be confirmed via abstract retrieval at seeding time. Verifier should check this specific source. unsourced
DOPAL-detox vs retinoid function: The relative contribution of ALDH1A1’s two protective mechanisms in dopaminergic neurons (atRA synthesis vs DOPAL detoxification) has not been cleanly separated in vivo. no-mechanism
Druggability tier not Open Targets-confirmed. Tier-2 is based on probe literature; verify via Open Targets ENSG00000165092 on verification pass. no-opentargets-entry
retinoid-signaling pathway page is a stub. The canonical pathway for this protein’s downstream biology has not been seeded. stub

Footnotes

doi:10.1016/j.abb.2020.108256 · Pequerul R, Vera J, Giménez-Dejoz J et al. (Farrés lab) · Arch Biochem Biophys 2020;681:108256 · structural/kinetic characterization · ALDH1A1/1A2/1A3 side-by-side kinetic comparison with retinoid and non-retinoid substrates; Cys303 active-site nucleophile confirmed; 4-HNE detox: ALDH1A2 is best enzyme for 4-HNE in terms of kcat/Km, not ALDH1A1; isoform substrate-binding pocket volumes differ (534 / 387 / 387 Å³ for 1A1/1A2/1A3) · Note: NCT-501 selectivity data not in this paper — NCT-501 requires separate citation · green OA · locally available ↩ ↩² ↩³
doi:10.3390/nu6030950 · Petrosino JM, DiSilvestro D, Ziouzenkova O · Nutrients 2014;6(3):950–973 · review · ALDH1A1 metabolism, retinoid biosynthesis, sex-specific adipose regulation (female-specific focus); ALDH1A1 expression higher in females in fat depots; proposes estrogen→retinoid “horizontal signal transfer” via ALDH1A1 · gold OA · locally available ↩ ↩²
doi:10.1007/s00441-006-0376-3 · Fujiwara K et al. · Cell Tissue Res 2007;328(1):129–135 · developmental expression study (rat) · RALDH2 and RALDH3 but not RALDH1 expressed in embryonic anterior pituitary; supports RALDH1 as postnatal-dominant isoform ↩
doi:10.1073/pnas.0603806103 · Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, McDonnell DP · PNAS 2006;103(31):11707–11712 · ex-vivo (human CB CD34+CD38− HSCs) + in-vivo NOD/SCID · DEAB inhibition of ALDH (specifically ALDH1) → 3.4-fold expansion of SCID-repopulating cells (SRCs) in short-term culture; reversed by exogenous ATRA (1 µM) and by the RAR-specific agonist TTNPB; engraftment potential retained · green OA · locally available ↩
doi:10.1167/iovs.04-0120 · Choudhary S, Xiao T, Vergara LA, Srivastava S, Nees D, Piatigorsky J, Ansari NH · Invest Ophthalmol Vis Sci 2005;46(1):259–267 · in-vitro/ex-vivo (rat lens + human lens epithelial cells) · ALDH isozymes critical for defense against oxidative stress in lens; role in 4-HNE detoxification; inhibition accelerates oxidative damage ↩
doi:10.1002/jnr.22307 · Zhang M et al. · J Neurosci Res 2010;88(3):686–694 · in-vitro (SH-SY5Y neuroblastoma) · ALDH1A1 overexpression reduces protein-HNE adducts and caspase-3 activation under oxidative challenge ↩
doi:10.1016/j.celrep.2014.10.008 · Poulin JF, Zou J, Drouin-Ouellet J, Kim KY, Cicchetti F, Awatramani RB · Cell Reports 2014;9:930–943 · single-cell qPCR profiling (mouse midbrain DA neurons, n=159 cells, 96 genes/cell) · ALDH1A1+ (DA1A subtype) SNc neurons defined as molecularly distinct; 66.2% diminution of Aldh1a1+ cells in MPTP-treated vs saline mice (p=0.001); remaining DA neurons (DA1B, less Aldh1a1) only 39.1% loss · gold OA · locally available ↩
doi:10.1186/s13024-023-00699-0 · Martirosyan A, Ansari R, Pestana F et al. · Mol Neurodegeneration 2024;19(1):7 · snRNA-seq observational (human, 15 sporadic PD / 14 controls; 83,484 high-quality nuclei after QC) · ALDH1A1 is one of 28 cell markers shared across multiple TH-enriched depleted cell types (Neurons0 + Astrocytes2 + Microglia1 + Oligos2) in PD; ALDH1A1 also listed as a Neurons0 (dopaminergic) subpopulation marker · gold OA · locally available ↩
doi:10.1016/j.bbalip.2011.06.004 · Yasmeen R, Ziouzenkova O · BBA Mol Cell Biol Lipids 2012;1821(1):190–197 · review · 69 citations · ALDH1A1 synthesis of atRA in adipose tissue opposes PPARγ-driven adipogenesis · pending local download ↩
doi:10.1371/journal.pone.0187669 · Yang D, Napoli JL · PLoS ONE 2017;12(11):e0187669 · in-vivo (Raldh1 KO mouse) + LC/MS/MS · 18 citations · Raldh1 promotes adolescent adiposity via retinal-independent mechanism · gold OA · pending local download ↩

🧬 Aging Wiki

Explorer

aldh1a1